Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study

Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study

Purpose TFE3-rearranged/TFEB-altered renal cell carcinoma (RCC) is a rare subtype of RCC. Due to its rarity, there is an unmet medical need for effective therapies in advanced settings. The study aims to investigate the clinical and histopathological characteristics of patients with microphthalmia t...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Joohyun Hong, Ghee Young Kwon, Minyong Kang, Seong Il Seo, Se Hoon Park
التنسيق:	مقال
اللغة:	English
منشور في:	Korean Urological Oncology Society 2024-03-01
سلاسل:	Journal of Urologic Oncology
الموضوعات:	-rearranged -altered renal cell carcinoma tyrosine kinase inhibitors immune checkpoint inhibitors
الوصول للمادة أونلاين:	http://www.e-juo.org/upload/pdf/juo-234600660033.pdf

مواد مشابهة

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
حسب: Huang JT, وآخرون
منشور في: (2022-11-01)

Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience
حسب: Pan X, وآخرون
منشور في: (2023-06-01)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
حسب: Fei Yang, وآخرون
منشور في: (2022-01-01)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma
حسب: Hongyu Pan, وآخرون
منشور في: (2025-03-01)

Efficacy of the immune checkpoint inhibitor nivolumab in the treatment of advanced hepatocellular carcinoma with the exhausted possibilities of therapy with tyrosine kinase inhibitors
حسب: A. Yu. Goryainova, وآخرون
منشور في: (2021-12-01)

Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
حسب: Gao B, وآخرون
منشور في: (2023-12-01)

Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors
حسب: Ning Luo, وآخرون
منشور في: (2023-08-01)

Additive toxicity arising from combined use of immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with renal or endometrial carcinoma: Protocol for a rapid systematic review
حسب: Shannon E. Kelly, وآخرون
منشور في: (2024-06-01)

Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study
حسب: Guosheng Yuan, وآخرون
منشور في: (2024-03-01)

Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?
حسب: Sang Youn Hwang, وآخرون
منشور في: (2023-11-01)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
حسب: Christopher Kwok, وآخرون
منشور في: (2023-07-01)

Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study
حسب: Junfeng Bu, وآخرون
منشور في: (2025-02-01)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
حسب: Karam Khaddour, وآخرون
منشور في: (2020-10-01)

Prognostic value of platelet-to-lymphocyte ratio in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization and tyrosine kinase inhibitors plus immune checkpoints inhibitors
حسب: Yiwan Guo, وآخرون
منشور في: (2024-01-01)

Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis
حسب: David O’Reilly, وآخرون
منشور في: (2024-07-01)

Advances in MET tyrosine kinase inhibitors in gastric cancer
حسب: Yifan Zhang, وآخرون
منشور في: (2024-06-01)

Prognostic value of the neutrophil-to-lymphocyte ratio and prognostic nutritional index in unresectable hepatocellular carcinoma patients treated with tyrosine kinase inhibitors and immune checkpoint inhibitors
حسب: Shasha Sun, وآخرون
منشور في: (2024-12-01)

Enhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors
حسب: Emmy D. G. Fleuren, وآخرون
منشور في: (2021-11-01)

Newly emerged ROS1 rearrangement in a patient with lung adenocarcinoma following resistance to immune checkpoint inhibitors: a case report
حسب: Jian Wang, وآخرون
منشور في: (2024-12-01)

Interventional therapy combined with tyrosine kinase inhibitors with or without immune checkpoint inhibitors as initial treatment for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis
حسب: Changjie Du, وآخرون
منشور في: (2024-05-01)

A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma
حسب: Renguo Guan, وآخرون
منشور في: (2022-09-01)

Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
حسب: Yuhang Chen, وآخرون
منشور في: (2024-12-01)

The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review
حسب: Qiao Ke, وآخرون
منشور في: (2022-05-01)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
حسب: Ling Peng, وآخرون
منشور في: (2022-04-01)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
حسب: Yue Chen, وآخرون
منشور في: (2022-06-01)

Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization
حسب: Halil Ibrahim Onder, وآخرون
منشور في: (2014-04-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
حسب: Ichiro Yamauchi, وآخرون
منشور في: (2025-01-01)

Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor
حسب: Daniela R. Montagna, وآخرون
منشور في: (2022-08-01)

Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy
حسب: Pottayil G. Sasikumar, وآخرون
منشور في: (2020-12-01)

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
حسب: Ryo Ariyasu, MD, وآخرون
منشور في: (2023-06-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
حسب: Yi-fan Chen, وآخرون
منشور في: (2011-12-01)

A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study
حسب: Kexue Deng, وآخرون
منشور في: (2022-09-01)

Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis
حسب: Jingyang Su, وآخرون
منشور في: (2024-04-01)

Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis
حسب: Eva Zhang, وآخرون
منشور في: (2021-05-01)

Recent Advances in Immune Checkpoint Inhibitor-associated Pneumonitis
حسب: CHEN Shuangqing, وآخرون
منشور في: (2022-10-01)

A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature
حسب: Qi Zhu, وآخرون
منشور في: (2022-05-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
حسب: Hanping Wang, وآخرون
منشور في: (2020-01-01)

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
حسب: Yuanquan Yang, وآخرون
منشور في: (2022-08-01)

Fatal Case of Immune-Related Myocarditis and Myositis Due to Treatment with Immune Checkpoint and Tyrosine Kinase Inhibitors
حسب: João Queirós Coelho, وآخرون
منشور في: (2024-10-01)

Targeting tumour microenvironment by tyrosine kinase inhibitor
حسب: Hor-Yue Tan, وآخرون
منشور في: (2018-02-01)